Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC2-selective ligands

Molecular Pharmacology

Volumn 56, Issue 6, 1999, Pages 1280-1287

  Juarranz, Maria G ^a   Van Rampelbergh, Jean ^a   Gourlet, Philippe ^a   De Neef, Philippe ^a   Cnudde, Johnny ^a   Robberecht, Patrick ^a   Waelbroeck, Magali ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEXANOIC ACID; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ACYLATION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHIMERA; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FOLDING;

EID: 0032732064     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.6.1280     Document Type: Article

References (29)

1. Ciccarelli E, Vilardaga JP, De Neef P, Di Paolo E, Waelbroeck M, Bollen A and Robberecht P (1994) Properties of the VIP-PACAP type II receptor stably expressed in CHO cells. Regul Pept 54:397-407.
2. Colquhoun D (1999) Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125:924-947.
3. Couvineau A, Rouyer-Fessard C, Darmoul D, Maoret JJ, Carrero I, Ogier-Denis E and Laburthe M (1994) Human intestinal VIP receptor: Cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun 200:769-776.
4. Di Paolo E, De Neef P, Moguilevsky N, Petry H, Bollen A, Waelbroeck M and Robberecht P (1998) Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin. FEBS Lett 424:207-210.
5. Di Paolo E, Petry H, Moguilevsky N, Bollen A, De Neef P, Waelbroeck M and Robberecht P (1999) Mutations of aromatic residues in the first transmembrane helix impair signalling by the secretin receptor. Receptors Channels 6:309-315.
6. Dong M, Wang Y, Pinon DI, Hadac EM and Miller LJ (1999) Demonstration of a direct interaction between residue 22 in the carboxyl-terminal half of secretin and the ammo-terminal tail of the secretin receptor using photoaffinity labeling. J Biol Chem 274:903-909.
7. 1 receptor. Peptides 18:1555-1560.
8. 2/PACAP receptors. Eur J Pharmacol 354:105-111.
9. 2 recombinant receptors. Regul Pept 62:125-130.
10. 1 receptor agonist. Peptides 18:1539-1545.
11. 2 receptor subclass. Peptides 18:403-408.
12. Gourlet P, Vilardaga JP, De Neef P, Vandermeers A, Waelbroeck M, Bollen A and Robberecht P (1996b) Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor. Eur J Biochem 239:349-355.
13. Gozes I and Fridkin M (1992) A fatty neuropeptide: Potential drug for noninvasive impotence treatment in a rat model. J Clin Invest 90:810-814.
14. Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, Davidson A, Rubinraut S, Fridkin M and Brenneman DE (1995) Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptor. J Pharmacol Exp Ther 273:161-167.
15. Gozes I, Reshef A, Salah D, Rubinraut S and Fridkin M (1994) Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel analog for noninvasive impotence treatment. Endocrinology 134:2121-2125.
16. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA and Waschek JA (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265-270.
17. Hashimoto H, Ogawa N, Hagihara N, Yamamoto K, Imanishi K, Nogi H, Nishino A, Fujita T, Matsuda T, Nagata S and Baba A (1997) Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. Mol Pharmacol 52:128-135.
18. Ishihara T, Shigemoto R, Mori K, Takahashi K and Nagata S (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8:811-819.
19. Robberecht P, Gourlet P, Vertongen P and Svoboda M (1996) Characterization of the VIP receptor from SUP-T1 lymphoblasts. Adv Neuroimmunol 6:49-57.
20. Salomon Y, Londos C and Rodbell M (1974) A highly sensitive adenylate cyclase assay. Anal Biochem 58:541-548.
21. Svoboda M, Tastenoy M, Van Rampelbergh J, Goossens JF, De Neef P, Waelbroeck M and Robberecht P (1994) Molecular cloning and functional characterization of a VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 205: 1617-1627.
22. Usdin TB, Bonner TI and Mezey E (1994) Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135:2662-2680.
23. 1 receptors: Evidence for multiple receptor states. Mol Pharmacol 60:1596-1604.
24. Vertongen P, Delhase M, Rajas F, Trouillas J, Hooghe-Peters E, Svoboda M and Robberecht P (1996) Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumors (SWtTW) and in normal gland. J Mol Endocrinol 16: 239-248.
25. Vertongen P, Schiffmann SN, Gourlet P and Robberecht P (1997) Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides 18:1547-1554.
26. Vilardaga JP, De Neef P, Di Paolo E, Bollen A, Waelbroeck M and Robberecht P (1995) Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination. Biochem Biophys Res Commun 211:885-891.
27. Vilardaga JP, Di Paolo E, De Neef P, Waelbroeck M, Bollen A and Robberecht P (1996) Lysine 173 residues within the first exoloop of rat secretin receptor is involved in carboxylate moiety recognition of Asp 3 in secretin. Biochem Biophys Res Commun 218:842-846.
28. Xia M, Sreedharan SP, Bolin DR, Gaufo GO and Goetzl EJ (1997) Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J Pharmacol Exp Ther 281:629-633.
29. Zhou AT, Bessalle R, Bisello A, Nakamoto C, Rosenblatt M, Suva LJ and Chorev M (1997) Direct mapping of an agonist-binding domain within the parathyroid hormone/parathyroid hormone-related protein receptor by photoaffinity crosslinking. Proc Natl Acad Sci USA 94:3644-3649.